News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
XBiotech Begins Phase II Trial of Vilamakitug for Active Axial Spondyloarthritis
Tuesday, June 16, 2026XBiotech has announced that the US Food and Drug Administration FDA has completed its day review of the Investigational New Drug IND application for the VSPINE PT Phase II clinical trial without placing
Entera Presents Phase 1 Data Supporting Single-Tablet EB613 for Osteoporosis at ENDO 2026
Tuesday, June 16, 2026Entera Bio has presented new Phase clinical data at ENDO supporting the development of a singletablet version of EB its investigational oral parathyroid hormone PTH treatment for osteoporosis
Arialys Advances ART5803 Development with First Phase 2 Patient Dosed and FDA IND Clearance
Tuesday, June 16, 2026Arialys Therapeutics has announced key clinical and regulatory milestones for ART its investigational treatment for autoimmune neuropsychiatric diseases The company reported that the first patient with antiNMDA
PharmaEssentia Receives Taiwan Approval for BESREMi in Essential Thrombocythaemia
Thursday, June 11, 2026PharmaEssentia has received approval from Taiwans Ministry of Health and Welfare MOHW for BESREMi ropeginterferon alfabnjft to treat adult patients with essential thrombocythaemia ET
IMAAVY Shows Durable Haemoglobin Response in Phase 2/3 Study for Warm Autoimmune Haemolytic Anaemia
Thursday, June 11, 2026Johnson Johnson has reported positive results from the Phase ENERGY study showing that IMAAVY nipocalimabaahu achieved a statistically significant and durable haemoglobin response in patients with warm
FloBiotech Signs Agreement with UCLA Health to Advance Neurodegenerative Disease Treatments
Wednesday, June 10, 2026FloBiotech has entered into an agreement with UCLA Health to support the development of a new class of therapies for neurodegenerative diseases by targeting protective biological pathways involved in disease progression
Engitix and GSK Partner to Advance New Targets for Liver Fibrosis Treatment
Tuesday, June 09, 2026Engitix has entered into a strategic research collaboration and option agreement with GSK to identify and validate novel therapeutic targets aimed at promoting liver fibrosis regression
FDA Expands Approval of Pfizer’s HYMPAVZI for Additional Hemophilia A and B Patient Groups
Tuesday, June 09, 2026Pfizer has received approval from the US Food and Drug Administration FDA for an expanded indication of HYMPAVZI marstacimabhncq extending its use to patients aged years and older with hemophilia
Teva launches AHZANTIVE biosimilar to Eylea across Europe
Friday, June 05, 2026Teva Pharmaceutical Industries has launched AHZANTIVE aflibercept a biosimilar to Eylea in Europe expanding its biosimilars portfolio and strengthening its presence in the ophthalmology sector
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Friday, June 05, 2026Biogen has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to salanersen for the treatment of spinal muscular atrophy SMA
